Literature DB >> 7337909

Toxoplasmosis update and public health implications.

R Fayer.   

Abstract

Toxoplasma gondii has a coccidian life cycle in the intestine of domestic and wild felids that includes a series of asexual and sexual stages and an oocyst stage that is shed in the feces. Oocysts complete their development outside the body, eventually becoming infective for about 350 species of vertebrates including cats and man. The effects of climate on oocyst survival and the physical and biological means of oocyst dispersal are discussed. Infectivity and pathogenicity for livestock species vary. Acute disease results from rapidly multiplying tachyzoites that may be transmitted by carnivorism, transfusion, vertical transmission and other routes. Patent infections may persist for the life of a host as bradyzoites within tissue cysts. Bradyzoites initiate acute infection in other hosts after carnivorism or organ transplantation or in the same host after immunosuppression. Also discussed are: (a) prevalence of T. gondii in livestock as determined by digestion and serological techniques, (b) identification in humans as accomplished by isolation, serological and skin test techniques and (c) identification in cats as accomplished primarily by fecal examinations for oocysts infective for mice. Source of human infections, major outbreaks, treatment, effects on mental health and methods for preventing toxoplasmosis in man and livestock are listed.

Entities:  

Mesh:

Year:  1981        PMID: 7337909      PMCID: PMC1789993     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  41 in total

1.  Bovine toxoplasmosis: experimental infections.

Authors:  B L Munday
Journal:  Int J Parasitol       Date:  1978-08       Impact factor: 3.981

Review 2.  Toxoplasmosis: a review.

Authors:  S R Jones
Journal:  J Am Vet Med Assoc       Date:  1973-11-01       Impact factor: 1.936

3.  Toxoplasma infection and abortion in sheep associated with feeding of grain contaminated with cat faeces.

Authors:  J W Plant; N Richardson; G G Moyle
Journal:  Aust Vet J       Date:  1974-01       Impact factor: 1.281

4.  Congenital toxoplasmosis: a prospective study of 4,048 obstetric patients.

Authors:  A C Kimball; B H Kean; F Fuchs
Journal:  Am J Obstet Gynecol       Date:  1971-09-15       Impact factor: 8.661

5.  Soil survival of toxoplasma oocysts in Kansas and Costa Rica.

Authors:  J K Frenkel; A Ruiz; M Chinchilla
Journal:  Am J Trop Med Hyg       Date:  1975-05       Impact factor: 2.345

6.  The prevalence of toxoplasmosis on Pacific Islands, and the influence of ethnic group.

Authors:  G D Wallace
Journal:  Am J Trop Med Hyg       Date:  1976-01       Impact factor: 2.345

7.  Prolonged excretion of Toxoplasma gondii in semen of goats.

Authors:  J P Dubey; S P Sharma
Journal:  Am J Vet Res       Date:  1980-05       Impact factor: 1.156

8.  Behavioural abnormalities in Toxoplasma-infected mice.

Authors:  W M Hutchinson; M Bradley; W M Cheyne; B W Wells; J Hay
Journal:  Ann Trop Med Parasitol       Date:  1980-06

9.  An outbreak of toxoplasmosis linked to cats.

Authors:  S Stagno; A C Dykes; C S Amos; R A Head; D D Juranek; K Walls
Journal:  Pediatrics       Date:  1980-04       Impact factor: 7.124

10.  Experimental infection of bovines with oocysts of Toxoplasma gondii.

Authors:  A J Costa; F G Araujo; J O Costa; J D Lima; E Nascimento
Journal:  J Parasitol       Date:  1977-04       Impact factor: 1.276

View more
  14 in total

1.  Gestational and neonatal toxoplasmosis: regional seroprevalence in the United Arab Emirates.

Authors:  F K Dar; T Alkarmi; S Uduman; Y Abdulrazzaq; H Grundsell; P Hughes
Journal:  Eur J Epidemiol       Date:  1997-07       Impact factor: 8.082

2.  Mic1-3 Knockout Toxoplasma gondii is a good candidate for a vaccine against T. gondii-induced abortion in sheep.

Authors:  Marie-Noëlle Mévélec; Céline Ducournau; Alaa Bassuny Ismael; Michel Olivier; Edouard Sèche; Maryse Lebrun; Daniel Bout; Isabelle Dimier-Poisson
Journal:  Vet Res       Date:  2010-04-13       Impact factor: 3.683

3.  Seroprevalence of Toxoplasma gondii infection in domestic sheep and goats in Borno state, Nigeria.

Authors:  Joshua Kamani; Aliyu U Mani; Godwin O Egwu
Journal:  Trop Anim Health Prod       Date:  2009-10-31       Impact factor: 1.559

4.  Occurrence of anti-Toxoplasma gondii antibodies in female cattle in south-west of Iran.

Authors:  Hossein Hamidinejat; Masoud Ghorbanpour; Leily Nabavi; Mohammad Rahim Haji Hajikolaie; Mohammad Hossein Razi Jalali
Journal:  Trop Anim Health Prod       Date:  2009-12-01       Impact factor: 1.559

5.  Toxoplasmosis and border disease in 54 Swedish sheep flocks. Seroprevalence and incidence during one gestation period.

Authors:  A Lundén; U Carlsson; K Näslund
Journal:  Acta Vet Scand       Date:  1992       Impact factor: 1.695

6.  Congenital toxoplasmosis: epidemiologic features and control.

Authors:  A O Carter; J W Frank
Journal:  CMAJ       Date:  1986-09-15       Impact factor: 8.262

7.  Seroprevalence of Toxoplasma gondii in Sheep, Cattle and Horses in Urmia North-West of Iran.

Authors:  S Raeghi; A Akaberi; S Sedeghi
Journal:  Iran J Parasitol       Date:  2011-12       Impact factor: 1.012

8.  The first seroepidemiological study on Toxoplasma gondii in backyard pigs in Myanmar.

Authors:  Yu Nandi Thaw; Tin Aye Khaing; Kyaw San Linn; Soe Soe Wai; Lat Lat Htun; Saw Bawm
Journal:  Parasite Epidemiol Control       Date:  2021-06-05

9.  Seroprevalence and risk factors associated with ovine toxoplasmosis in Northeast Brazil.

Authors:  Milena M Clementino Andrade; Mariangela Carneiro; Andrea D Medeiros; Valter Andrade Neto; Ricardo W A Vitor
Journal:  Parasite       Date:  2013-05-28       Impact factor: 3.000

10.  Toxoplasma gondii decreases the reproductive fitness in mice.

Authors:  Katerina Dvorakova-Hortova; Adela Sidlova; Lukas Ded; Denisa Hladovcova; Markus Vieweg; Wolfgang Weidner; Klaus Steger; Pavel Stopka; Agnieszka Paradowska-Dogan
Journal:  PLoS One       Date:  2014-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.